Eligibility for mepolizumab, omalizumab and reslizumab in the EU population: The IDEAL Study

Authors
Publication date
23 February 2017
Publisher
Georg Thieme Verlag KG
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1055%2Fs-0037-1598...
      Last time updated on 21/04/2021